Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
5g |
|
||
Other Sizes |
|
ln Vitro |
Mepivacaine hydrochloride inhibits sodium influx and membrane depolarization by binding to particular voltage-gated sodium channels in the membranes of neuronal cells. This leads to reversible sensory loss and a blockage in the beginning and conduction of nerve impulses. This medication acts more quickly and lasts for a moderate amount of time when compared to other local anesthetics [2]. Compared to procaine, mepivacaine hydrochloride acts more quickly at first and for a longer amount of time in the middle [3]. Preferential usage-dependent blockage of Na(v)1.8 is demonstrated by mepivacaine hydrochloride, while TTX Na(+) channels are preferred by S(-)-bupivacaine [4].
|
---|---|
References |
[1]. Froehle M, et al. ECMO for Cardiac Rescue after Accidental Intravenous Mepivacaine Application. Case Rep Pediatr. 2012;2012:491692.
[2]. mepivacaine hydrochloride. [3]. Burm, A.G., et al., Pharmacokinetics of the enantiomers of mepivacaine after intravenous administration of the racemate in volunteers. Anesth Analg, 1997. 84(1): p. 85-9. [4]. Leffler, A., J. Reckzeh, and C. Nau, Block of sensory neuronal Na+ channels by the secreolytic ambroxol is associated with an interaction with local anesthetic binding sites. Eur J Pharmacol, 2010. 630(1-3): p. 19-28. |
Molecular Formula |
C15H23CLN2O
|
---|---|
Molecular Weight |
282.8089
|
CAS # |
1722-62-9
|
Related CAS # |
(+)-Mepivacaine;24358-84-7;Mepivacaine;96-88-8
|
SMILES |
Cl[H].O=C(C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1C([H])([H])[H])N([H])C1C(C([H])([H])[H])=C([H])C([H])=C([H])C=1C([H])([H])[H]
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~100 mg/mL (~353.59 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (353.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.5359 mL | 17.6797 mL | 35.3594 mL | |
5 mM | 0.7072 mL | 3.5359 mL | 7.0719 mL | |
10 mM | 0.3536 mL | 1.7680 mL | 3.5359 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.